Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKinsey
Boehringer Ingelheim
Merck
Harvard Business School

Last Updated: February 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for INCB039110


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug INCB039110?

INCB039110 is an investigational drug.

There have been 34 clinical trials for INCB039110. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2017.

The most common disease conditions in clinical trials are Graft vs Host Disease, Carcinoma, Non-Small-Cell Lung, and Lung Neoplasms. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are twenty US patents protecting this investigational drug and two hundred and seventeen international patents.

Recent Clinical Trials for INCB039110
TitleSponsorPhase
Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell TransplantNational Cancer Institute (NCI)Phase 1
Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell TransplantM.D. Anderson Cancer CenterPhase 1
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell TransplantationNational Cancer Institute (NCI)Phase 2

See all INCB039110 clinical trials

Clinical Trial Summary for INCB039110

Top disease conditions for INCB039110
Top clinical trial sponsors for INCB039110

See all INCB039110 clinical trials

US Patents for INCB039110

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
INCB039110   Start Trial Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE)   Start Trial
INCB039110   Start Trial Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation (Wilmington, DE)   Start Trial
INCB039110   Start Trial Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors Incyte Corporation (Wilmington, DE)   Start Trial
INCB039110   Start Trial Heterocyclic compounds as PI3K-.gamma. inhibitors Incyte Corporation (Wilmington, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for INCB039110

Drugname Country Document Number Estimated Expiration Related US Patent
INCB039110 World Intellectual Property Organization (WIPO) 2017027717 2035-08-12   Start Trial
INCB039110 World Intellectual Property Organization (WIPO) 2017035366 2035-08-26   Start Trial
INCB039110 Australia 2015244044 2034-04-08   Start Trial
INCB039110 Canada 2945151 2034-04-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Express Scripts
McKinsey
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.